$CMAXQ
CareMax, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022009004 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $136.9M $118.3M $27.92M
YoY Change 390.44%
Cost Of Revenue $120.2M $102.5M $23.51M
YoY Change 411.25%
Gross Profit $16.72M $15.84M $4.406M
YoY Change 279.37%
Gross Profit Margin 12.21% 13.39% 15.78%
Selling, General & Admin $22.28M $18.93M $2.086M
YoY Change 968.02% 405.97%
% of Gross Profit 133.29% 119.52% 47.34%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.100M $6.070M $211.0K
YoY Change 421.33%
% of Gross Profit 6.58% 38.33% 4.79%
Operating Expenses $147.8M $25.02M $26.11M
YoY Change 466.07% 568.71%
Operating Profit -$10.89M -$9.181M $1.806M
YoY Change -702.99%
Interest Expense -$1.728M $6.830M -$504.0K
YoY Change 242.86% -138.93%
% of Operating Profit -27.91%
Other Income/Expense, Net -$462.0K -$495.0K
YoY Change
Pretax Income -$16.62M -$3.397M $1.302M
YoY Change -1376.19% -84.04%
Income Tax $181.0K $159.0K $0.00
% Of Pretax Income 0.0%
Net Earnings -$16.80M -$3.556M $1.302M
YoY Change -1390.09% -83.29% -58.94%
Net Earnings / Revenue -12.27% -3.01% 4.66%
Basic Earnings Per Share -$0.19 $0.12
Diluted Earnings Per Share -$0.19 -$40.44K $0.12
COMMON SHARES
Basic Shares Outstanding 87.37M 10.80M
Diluted Shares Outstanding 87.37M 10.80M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.74M $47.92M $390.0K
YoY Change 8294.44% 5173.08%
Cash & Equivalents $32.74M $47.92M $6.435M
Short-Term Investments
Other Short-Term Assets $20.70M $17.58M $209.6K
YoY Change 9774.54% 8770.67%
Inventory $702.0K $550.0K
Prepaid Expenses $20.05M $17.04M
Receivables $53.58M $42.00M
Other Receivables $0.00 $0.00
Total Short-Term Assets $107.7M $108.0M $599.7K
YoY Change 17864.31% 626.05%
LONG-TERM ASSETS
Property, Plant & Equipment $16.90M $15.99M
YoY Change 233.47%
Goodwill $464.3M $464.6M
YoY Change 4514.28%
Intangibles $55.60M $59.81M
YoY Change 597.5%
Long-Term Investments $143.9M
YoY Change
Other Assets $2.738M $2.706M
YoY Change 1378.69%
Total Long-Term Assets $541.4M $545.0M $143.9M
YoY Change 276.32% 2207.37%
TOTAL ASSETS
Total Short-Term Assets $107.7M $108.0M $599.7K
Total Long-Term Assets $541.4M $545.0M $143.9M
Total Assets $649.1M $653.1M $144.5M
YoY Change 349.33% 1596.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.165M $3.110M $456.7K
YoY Change 1031.06% 197.89%
Accrued Expenses $12.37M $8.690M $4.355M
YoY Change 183.93% 237.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.272M $6.275M
YoY Change 525.0%
Total Short-Term Liabilities $28.14M $21.96M $4.861M
YoY Change 478.83% 302.84%
LONG-TERM LIABILITIES
Long-Term Debt $109.7M $111.0M $0.00
YoY Change 321.5%
Other Long-Term Liabilities $7.186M $6.428M $18.31M
YoY Change -60.76% -77.99%
Total Long-Term Liabilities $116.8M $117.4M $18.31M
YoY Change 538.04% 345.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.14M $21.96M $4.861M
Total Long-Term Liabilities $116.8M $117.4M $18.31M
Total Liabilities $156.9M $147.7M $23.17M
YoY Change 577.02% 364.89%
SHAREHOLDERS EQUITY
Retained Earnings -$16.76M $33.00K
YoY Change
Common Stock $509.0M $505.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $492.2M $505.4M $8.028M
YoY Change
Total Liabilities & Shareholders Equity $649.1M $653.1M $144.5M
YoY Change 349.33% 1596.21%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$16.80M -$3.556M $1.302M
YoY Change -1390.09% -83.29% -58.94%
Depreciation, Depletion And Amortization $1.100M $6.070M $211.0K
YoY Change 421.33%
Cash From Operating Activities -$12.14M -$15.05M $3.372M
YoY Change -459.99% 18984.69%
INVESTING ACTIVITIES
Capital Expenditures $1.467M -$3.905M $1.690M
YoY Change -13.2%
Acquisitions
YoY Change
Other Investing Activities -$11.36M
YoY Change
Cash From Investing Activities -$1.467M -$15.27M -$1.690M
YoY Change -13.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.570M -2.212M -181.0K
YoY Change 767.4%
NET CHANGE
Cash From Operating Activities -12.14M -15.05M 3.372M
Cash From Investing Activities -1.467M -15.27M -1.690M
Cash From Financing Activities -1.570M -2.212M -181.0K
Net Change In Cash -15.18M -32.53M 1.501M
YoY Change -1111.06% 41144.93%
FREE CASH FLOW
Cash From Operating Activities -$12.14M -$15.05M $3.372M
Capital Expenditures $1.467M -$3.905M $1.690M
Free Cash Flow -$13.61M -$11.15M $1.682M
YoY Change -908.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39391
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001813914
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
CareMax, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0992224
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1000 NW 57 Court
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33126
CY2022Q1 dei City Area Code
CityAreaCode
786
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
360-4768
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q1 us-gaap Cash
Cash
32740000
CY2021Q4 us-gaap Cash
Cash
47917000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
53581000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41998000
CY2022Q1 us-gaap Inventory Net
InventoryNet
702000
CY2021Q4 us-gaap Inventory Net
InventoryNet
550000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
20045000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17040000
CY2022Q1 cmax Risk Settlements Due From Providers Current
RiskSettlementsDueFromProvidersCurrent
655000
CY2021Q4 cmax Risk Settlements Due From Providers Current
RiskSettlementsDueFromProvidersCurrent
539000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
107723000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
108044000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16895000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15993000
CY2022Q1 us-gaap Goodwill
Goodwill
464264000
CY2021Q4 us-gaap Goodwill
Goodwill
464566000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
55604000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59811000
CY2022Q1 us-gaap Deferred Costs
DeferredCosts
1860000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
1972000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2738000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2706000
CY2022Q1 us-gaap Assets
Assets
649085000
CY2021Q4 us-gaap Assets
Assets
653092000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5165000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3110000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12365000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8690000
CY2022Q1 cmax Risk Settlements Due To Providers Current
RiskSettlementsDueToProvidersCurrent
228000
CY2021Q4 cmax Risk Settlements Due To Providers Current
RiskSettlementsDueToProvidersCurrent
196000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6272000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6275000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4107000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3687000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
28137000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21959000
CY2022Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
11911000
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
8375000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
109660000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
110960000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7186000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6428000
CY2022Q1 us-gaap Liabilities
Liabilities
156895000
CY2021Q4 us-gaap Liabilities
Liabilities
147722000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
508945000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
505327000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16763000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
33000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
492190000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
505370000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
649085000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
653092000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
136920000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27918000
CY2022Q1 cmax Health Care Organization External Provider Costs
HealthCareOrganizationExternalProviderCosts
92856000
CY2021Q1 cmax Health Care Organization External Provider Costs
HealthCareOrganizationExternalProviderCosts
18159000
CY2022Q1 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
27349000
CY2021Q1 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
5353000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3301000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
291000
CY2022Q1 cmax Corporate General And Administrative
CorporateGeneralAndAdministrative
18978000
CY2021Q1 cmax Corporate General And Administrative
CorporateGeneralAndAdministrative
1795000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5062000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
514000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
266000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
147811000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
26112000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10890000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1806000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1728000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-504000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3536000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-462000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16616000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1302000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
181000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16797000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
1302000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87367972
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10796069
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87367972
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10796069
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6727000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
1302000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
8028000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
505370000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1087000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2530000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16797000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
492190000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16797000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
1302000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5062000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
514000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
378000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
35000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1087000
CY2022Q1 cmax Gain Loss On Remeasurement Of Warrant Liabilities
GainLossOnRemeasurementOfWarrantLiabilities
-3536000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-202000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10992000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-639000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
152000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
475000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-15000
CY2022Q1 cmax Increase Decrease In Risk Settlements Due From Due To Providers
IncreaseDecreaseInRiskSettlementsDueFromDueToProviders
84000
CY2021Q1 cmax Increase Decrease In Risk Settlements Due From Due To Providers
IncreaseDecreaseInRiskSettlementsDueFromDueToProviders
281000
CY2021Q1 cmax Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
-392000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
52000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
205000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1470000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1160000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3675000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-134000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1002000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
720000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12139000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3372000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1467000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1690000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1467000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1690000
CY2022Q1 cmax Principal Payments On Long Term Debt
PrincipalPaymentsOnLongTermDebt
1570000
CY2021Q1 cmax Principal Payments On Long Term Debt
PrincipalPaymentsOnLongTermDebt
181000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1570000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-181000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15176000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1501000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47917000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4934000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32740000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6435000
CY2022Q1 cmax Noncash Vesting Of Series B Warrants Under Advisory Agreement
NoncashVestingOfSeriesBWarrantsUnderAdvisoryAgreement
2530000
CY2022Q1 cmax Additions To Construction In Progress Funded Through Accounts Payable
AdditionsToConstructionInProgressFundedThroughAccountsPayable
585000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1353000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
504000
CY2022Q1 cmax Number Of Wholly Owned Operating Multi Specialty Medical Centers
NumberOfWhollyOwnedOperatingMultiSpecialtyMedicalCenters
48
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. The Company bases its estimates on the available information, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The areas where significant estimates are used in the accompanying financial statements include, but are not limited to, purchase price allocations, including fair value estimates of intangibles and contingent consideration; the valuation of and related impairment testing of long-lived assets, including goodwill and intangible assets; the valuation of the derivative warrant liabilities; the estimated useful lives of fixed assets and intangible assets, including internally developed software; revenue recognition and liability for unpaid claims. Actual results could differ from those estimates.</span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company’s cash balances with individual banking institutions are in excess of federally insured limits from time to time. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our three largest payor relationships were with Anthem, Humana and Centene, which as of March 31, 2022 represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of our accounts receivable balance, respectively. As of December 31, 2021, Anthem, Humana and Centene represented represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of our accounts receivable balance, respectively. Anthem, Humana and Centene represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's revenues during the three months ended March 31, 2022 (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">86</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% during the three months ended March 31, 2021).</span></p>
CY2022Q1 cmax Reinsurance Premium Expense Incurred
ReinsurancePremiumExpenseIncurred
3700000
CY2021Q1 cmax Reinsurance Premium Expense Incurred
ReinsurancePremiumExpenseIncurred
412000
CY2022Q1 cmax Reinsurance Recoveries Recognized
ReinsuranceRecoveriesRecognized
6400000
CY2021Q1 cmax Reinsurance Recoveries Recognized
ReinsuranceRecoveriesRecognized
363000
CY2021Q4 us-gaap Goodwill
Goodwill
464566000
CY2022Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
302000
CY2022Q1 us-gaap Goodwill
Goodwill
464264000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
70852000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15248000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
55604000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
71141000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11331000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
59811000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3900000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
252000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23856000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21902000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6961000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5909000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16895000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15993000
CY2022Q1 us-gaap Depreciation
Depreciation
1100000
CY2021Q1 us-gaap Depreciation
Depreciation
211000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4438000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4704000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
115932000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
117236000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6272000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6275000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
109660000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
110960000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4706000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6265000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8611000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
11726000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
89063000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
120370000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16797000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1302000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87367972
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10796069
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87367972
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10796069
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18351
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
3500000
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q1 cmax Lessee Operating Lease Expiring Term Description
LesseeOperatingLeaseExpiringTermDescription
various times through 2033
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8381000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
13531000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
13440000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13130000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12556000
CY2022Q1 cmax Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
139501000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
200539000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4300000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
181000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011

Files In Submission

Name View Source Status
0000950170-22-009004-index-headers.html Edgar Link pending
0000950170-22-009004-index.html Edgar Link pending
0000950170-22-009004.txt Edgar Link pending
0000950170-22-009004-xbrl.zip Edgar Link pending
cmax-20220331.htm Edgar Link pending
cmax-20220331.xsd Edgar Link pending
cmax-20220331_cal.xml Edgar Link unprocessable
cmax-20220331_def.xml Edgar Link unprocessable
cmax-20220331_htm.xml Edgar Link completed
cmax-20220331_lab.xml Edgar Link unprocessable
cmax-20220331_pre.xml Edgar Link unprocessable
cmax-ex31_1.htm Edgar Link pending
cmax-ex31_2.htm Edgar Link pending
cmax-ex32_1.htm Edgar Link pending
cmax-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img230330315_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending